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The ability to generate functional artificial lymphoid tissue to induce specific immunity 
at ectopic sites would offer a potential breakthrough for treatment of diseases such as 
cancer and severe infection using immunotherapy. Artificial lymphoid tissue would 
also offer an informative tool to further study lymphoid tissue development and 
function in vivo. Here we review the process of secondary and tertiary lymphoid 
organization – for which an understanding will be essential for artificial lymphoid 
tissue synthesis. Using this knowledge, we consider the combination of cell types, 
soluble factors and scaffold properties that will enable proper accumulation and 
organization of lymphocytes into tissue grafts. Recent successes with trials for the in 
















Lymphoid tissue formation and induction of immunity 
The adaptive immune system responds to antigens to produce various outcomes such 
as tolerance, antigen-specific immunity and immunological memory. These immune 
responses are, in most cases, supported by secondary lymphoid organs (SLO), such as 
lymph nodes (LN), Peyer’s patches (PP) and the spleen, as well as tertiary lymphoid 
organs (TLO). In contrast to SLO, which develop during embryogenesis1,2, TLO form in 
the postnatal period in response to antigenic stimuli 3. Although TLO development is 
initiated by antigenic stimuli, the process partially recapitulates development of SLO 
during embryogenesis. For example, both SLO and TLO structures include segregated T 
and B cell accumulations, CD11c+ dendritic cell (DC) clusters, follicular dendritic cell 
(FDCs) networks, and high endothelial venules (HEV) 3,4. TLO formation occurs at 
ectopic sites and often accompanies the onset of acute and chronic inflammation, 
infection, autoimmune diseases and tumorogenesis, to provide a highly localized 
immune response against microbial-derived or autoanitgens. Examples of TLO include 
lymphoid tissue formation in the synovial membrane of rheumatoid arthritis 5-7, aorta 
adventitia of atherosclerosis 8,9 and salivary gland of Sjögren syndrome 10,11. TLOs have 
also been observed during organ transplant rejection, which raises the possibility that 
they contribute to T cell-dependent allograft rejection by serving as a site for local 
adaptive immune responses 12. To address this question, RIP-LTwhich offer a model 
for skin transplant were used. These mice express Lta (lymphotoxin ) under the 
control of the rat insulin promoter (RIP) and develop TLOs in the pancreatic islets, 
kidney and skin. RIP-LT mouse skin grafts (containing TLO) were transplanted into 
allogeneic splenectomized aly/aly host mice, which lack all SLO. The skin allograft with 
TLO containing host-derived lymphocytes was rejected. Thus, the TLOs support the 
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activation of naïve T cells to effector and memory T cells. The findings provide rationale 
for developing strategies to artificially synthesize lymphoid tissues at ectopic local sites, 
where a strong and specific immune response is desired. To synthesize functional 
artificial lymphoid tissues (aLT) at ectopic sites in vivo or in vitro, the regulated 
processes of SLO and TLO formation must be precisely understood. It will also be 
important to make use of advances in tissue engineering, with respect to both new 
technologies and biomaterials. Here, we provide an overview of SLO and TLO 
development, and then discuss trials to date for the in vivo induction of aLT.  
 
Lymphoid tissue-inducer (LTi) cells and lymphoid organ formation 
The physiological processes that drive SLO development have been well studied 1,2,13,14. 
During embryogenesis, lymphoid tissue formation is dependent on the interaction 
between hematopoietic CD45+ CD3- CD4+ LT12+ LTi cells and VCAM-1+ ICAM-1+ 
LTR+ stromal lymphoid tissue organizer (LTo) cells 1,13,15. LTi-like cells also contribute to 
lymphoid organogenesis in the adult 16. LTi cells express a variety of factors important 
for organogenesis including the surface molecules IL-7R, common gamma chain, 
CXCR5, RANKL (TRANCE) and RANK, and transcriptional factors such as RORC and 
Id216-22. Since both the mature embryonic LTi cells and adult LTi cells are recruited and 
maintained at the lymphoid tissue anlagen (during embroyogenesis) and at sites of 
chronic inflammation or infection (in the adult)18, they require the capacity to migrate 
through the vasculature. Indeed, whole embryonic spleens implanted under the renal 
subcapsular space of adult mice induce lymphoid tissue formation through 
accumulation of host-derived T cells, B cells and DCs. Host LTi cells are also recruited, 
which leads to stimulation of the grafted LTo cells and the production of CCL21 which 
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attracts naïve T cells and DCs 23. These findings suggest that the circulating adult LTi 
cells migrate into the grafts and interact with embryonic stromal cells to organize 
splenic white pulp formation 23. In human fetal tissues, LTi cells have been identified as 
lineage- RORC+ IL-7R+ hematopietic cells. They are able to stimulate the expression of 
VCAM-1 and ICAM-1 on human mesenchymal stem cells in vitro, through expression of 
LT12, which triggers LTR signaling in LTo cells 24. 
 
LTo in SLO and TLO 
In contrast to LTi cells, the VCAM-1+ ICAM-1+ LTR+ LTo stromal cells are adherent cells 
that are non-hematopoietic and can be categorized according to heterogeneous 
functions 25. In SLO and TLO, two important stromal cells play a specialized role in 
lymphoid tissue formation: the FDC in B cell follicles and the fibroblastic reticular cells 
(FRC) in the T cell area. Their precise immunological contributions have been detailed 
in a recent review 25. In the T cell area, FRC networks, and their conduit system, form 
three-dimensional structures that provide tracks for T cell migration, which is regulated 
by CCR7. FRCs are the source of survival factors such as CCL19, IL-6 and IL-7, as well as 
mediators such as VEGF26 and retinoic acid (RA) that is produced by the enzyme 
RALDH2 27,28. RA leads to homing of activated T cells through activation of DCs 29. VEGF 
induces proliferation of endothelial cells and maintains blood vessels25. The conduit 
system is sheathed and interconnected by FRC and is also linked to lymphatic vessels 
with fluid flow at draining lymph nodes (LN). Using three dimensional LN T cell areas 
that were constructed in vitro using FRC clones cultured together with type I collagen 
and matrigel, it was shown that fluid flow in the in vitro structures was required for 
CCL21 secretion from FRC, which enhanced the organization of FRC networks 30. In vivo 
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analysis by the same authors also indicated that blocking lymph flow in peripheral LN 
decreased CCL21 and CCL19 gene expression in FRC. These data suggest that under 
conditions of increased lymph flow, for example during inflammation, FRC networks 
increase in complexity, which could activate immune cell trafficking, lymph sampling 
and induction of immune responses 30. In inflammation foci, it has been shown that 
local resident fibroblasts 31 and aortic smooth muscle cells 8,9 give rise to LTo-like 
stromal cells, which express chemokines such as CXCL13, CCl19 and CCL21 and 
recapitulate SLO formation after triggering of the LTR signaling pathway. Very recently, 
it was reported that lymph node FRC ectopically express and directly present 
peripheral tissue antigen (PTA) to naïve T cells under steady-state as well as 
inflammatory conditions 32. Another report also documented that lymph node-resident 
lymphatic endothelial cells directly present PTA to T cells and mediate peripheral 
tolerance in an Aire-independent manner 33. These reports suggest that diverse stromal 
cell types exist that constitutively express PTA, and that lymph node stromal cells are 
involved in the maintenance of tolerance to self-antigens in the periphery. Thus, for the 
purpose of generating aLT with different immunological functions, including regulatory 
activity, it will be crucial to clarify the stromal cell heterogeneity in lymphoid organs. 
 
Maintaining a microenvironment for lymphoid tissues formation 
The initiation of lymphoid organ formation is triggered by the interaction of 
lymphotoxin 12 (LT12) expressed on LTi cells with lymphotoxin-receptor (LTR) 
on the LTo cells at the lymphoid anlagen, which leads to activation of the NF-B 
signaling pathway. LTR ligation activates expression of the adhesion molecules 
VCAM-1, ICAM-1 and MAdCAM-1, as well as lymphoid chemokines such as CCL19, 
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CCL21 and CXCL13 34,35. LTR signaling events also promotes LTo cell expression of 
RANKL and IL-7, and binding of these ligands to their respective receptors on the newly 
recruited immature LTi cells acts to further induce LT12. This provides a positive 
feedback loop for lymphoid organ development at anlagen. Furthermore, the 
production of VEGF-C is induced in LTo cells, which contributes to lymphangiogenesis at 
this developmental stage 35, as shown in Figure-1A. LTR associated signaling 
molecules also include TRAF2, TRAF3, the classical IκB kinase complex containing IKKα, 
IKKβ, IKKγ, and ELKs and NF-κB-inducing kinase. Two recent studies suggest that TRAF3 
is a dual-mode regulator acting downstream of LTR to operate both canonical and 
non-canonical NF-B signaling pathways 36, and is critical for B cell homeostasis in SLO 
37. Thus, LTR signaling broadly contributes not only to lymphoid organ development 
but also to the maintenance of proper microenvironments wherein hematopoietic cells 
can home and interact. In influenza virus-infected mouse respiratory tracts, ectopic 
lymphoid tissues known as inducible bronchus-associated lymphoid tissues (iBALT) 
form through accumulation of lymphocytes and dendritic cells. CD11c+ DC depletion 
from the lung leads to the gradual disappearance of B220+ cells from the iBALT 
structure and a decrease of peanut agglutinin (PNA)-positive germinal center B cells, 
followed by diminution in the level of local immunoglobulin class switching. This 
suggests that CD11c+ DCs support maintenance of iBALT structure and function 38, 
indicating that CD11c+ DCs are involved in TLO organogenesis in addition to LTo stromal 
cells. 
 
For proper lymphoid organogenesis, spatiotemporal regulation of the cells and 
molecules that localize and function in the lymphoid anlagen is required. Recently, it 
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has been reported that heparan sulfate proteoglycans (HSPGs) play an important role 
in lymphoid development 39. HSPGs are molecules that contribute to several regulatory 
mechanisms during tissue morphogenesis by specifically binding soluble factors. In this 
regard, a number of lymphoid chemokines contain HSPGs binding motifs 40,41. Heparan 
sulfate (HS) glucuronyl C5-epimerase (Glce) mutant mice, which lack proper HS 
modifications, suffer from splenic hypoplasia, peripheral LN deletion, blood vessel 
mis-location and excess branching around peripheral LNs 39. These results indicate that 
SLO development requires a tightly organized process that combines the signaling 
pathways required for accumulation of hematopoietic cells, together with suitable 
mechanisms for retention of both lymphoid cells and bioactive molecules within the 
developing lymphoid organ. It will be important to take these findings into account 
when generating synthetic immune tissues. 
 
Contributions of chemokines to lymphoid tissue generation 
Both SLO and TLO possess organized structures, which include T and B cell areas, DCs, 
FDC networks and vascular networks. To initiate SLO and TLO development and to 
sustain their function, lymphoid chemokines play important roles in the migration and 
proper positioning of these lymphoid tissue-associated cells [Figure 1B]. In mice, CCL19 
and CCL21 expressed by FRC, and DCs attract and retain T cells within the appropriate 
area of the lymphoid tissues. Mice lacking both of CCL19 and CCL21, or mice lacking 
their receptor CCR7, retain LNs and PPs but exhibit defects in T cell trafficking to these 
lymphoid tissues, and in nasopharynx-associated lymphoid tissue maturation 42,43. By 
performing immunohistochemical analysis of human SLO and TLO in inflammatory 
lesions, it was demonstrated that CCL19 and CCL21 are both expressed by the smooth 
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muscle actin-positive stromal cells that are found in close proximity to HEVs, and CCL21 
is also expressed by mature DCs and lymphatic vessels 44. CXCL12, the ligand for CXCR4, 
also contributes to T cell trafficking into LNs and PPs in collaboration with CCR7 ligands 
43. Another important chemokine is CXCL13, which is expressed by stromal cells 
including FDCs. CXCL13 initiates lymphoid organ formation 45, entrance of B cells into 
follicles, and increased expression of LT12 on B cells. CXCL13 further facilitates 
CXCL13 expression in B cells, establishing a positive feedback loop for B cell follicle 
homeostasis 46. Mice deficient for both CXCL13 and IL-7R lack most LNs, but CXCL13 
is sufficient to recruit LTi cells to ectopic sites in vivo 47. These results, along with the 
IL-7R-mediated LT12 up-regulation on LTi cells, suggest that both CXCL13 and 
IL-7R contribute to accumulation and activation of LTi cells respectively during the 
initial LTR signaling-dependent stage in LN development 47. It has been shown, 
however, that in E12.5-14.5 LN anlagen, CXCL13 expression in LTo cells is induced by 
retinoic acid RA in a LTR signaling-independent manner. A possible source of RA 
appears to be cells of the nervous system around the LN anlagen 45. In the SLO and TLO 
microenvironment, B cells circulate throughout B cell follicles to survey antigens. Once 
B cells engage antigens, the antigen-specific B cells increase CCR7 and CXCR5 
expression, leading to their migration to the boundary between the B cell follicle and T 
cell zone, where B cells interact with antigen-specific T cells. Thus, controlled 
positioning of B cells in follicles is regulated by the finely-tuned responsiveness of B 
cells to chemokines such as CXCL13, CCL19 and CCL21 48. TLO formation was observed 
by ectopic expression of various chemokines such as CXCL12, CXCL13, CCL19 and CCL21 
in transgenic mice 49-51. Overexpression of each chemokine alone induced the complete 
formation of TLO. Ectopic expression of cytokines such as LT or IL-7 also formed TLO 
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52,53. Thus, certain chemokines and cytokines might be important and useful for 
generating artificial lymphoid tissues. 
 
Scaffolds for artificial lymphoid tissues  
Tissue engineering has received much attention in the field of regenerative medicine 
and is undergoing continuous innovation. The characteristics of available biomaterials 
play an important role in tissue engineering strategies, and have allowed for the 
construction of a variety of tissues including blood vessels 54,55, bone 56,57, spinal cord 58 
and peripheral nervous system 58,59. As a matter of course, this is now being applied to 
lymphoid tissues. Experimentally, to maintain the proper microenvironments at local 
sites, it will be necessary to attempt transplantation using scaffolds that: 1) contain the 
appropriate cell populations; 2) contribute to generation of lymphoid organs; 3) 
produce soluble factors such as lymphoid chemokines and cytokines that are 
expressed by stromal cells. A number of synthetic biomaterials are now able to 
duplicate the three dimensional microenvironments that are provided by natural 
extracellular matrices, such as fibrillar or non-fibrillar collagen, proteoglycans and 
matricellular proteins 60,61. It has been demonstrated that structurally-engineered 
macroporous scaffolds, which combine poly ethylene glycal hydrogels with collagen, 
support T cell and DCs migration 62. Further advances are being made in this area 60,61. 
The first in vivo synthesis of artificial lymphoid tissues was achieved using a porous 
biocompatible collagen matrix, prepared from bovine Achilles tendon (referred to as a 
collagen sponge) 63. This matrix has a non-homogeneous pore size ranging from 
50-300m. A difficulty in tissue engineering is the achieving the ability to properly 
modulate or mimick, dynamic tissue microenvironments, for example to achieve 
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appropriate cell recruitment or correct concentration gradients of soluble factors. As a 
first step toward this goal, biomaterials were recently described that are able to release 
several soluble factors, not only uniformly, but also gradually with temporal differences 
64. In this study, two growth factors were incorporated together into the same scaffolds 
by mixing PDGF-encapsulated polymer, lyophilized VEGF and non-treated polymer 
particles, so that the two growth factors were localized within distinct compartments. 
As a result, the scaffold could release the two factors with distinct kinetics and, after 
transplantation into subcutaneous tissue of Lewis rats, more mature vascular networks 
were structured than when using the scaffold which contained only a single growth 
factor 64. Two other recent studies have also reported that sustained 65 or 
spatiotemporal 66 delivery of growth factors can lead to formation of a mature vascular 
system. Thus, in order to efficiently generate artificial organized tissues, the scaffold 
microenvironment should be carefully constructed to be as close as possible to natural 
state.  
 
Generating artificial lymphoid tissue in vivo 
Generating functional artificial lymphoid tissues might be an important and beneficial 
method for making advances in immunotherapy, as well as for investigating the 
physiological functions of lymphoid tissues in vivo. For example, in the tumor 
microenvironment it is known that T cell immune responses are induced inside the 
tumor mass67. This, however, is not sufficient for tumor destruction due to 
immunosuppressive mechanisms. This immunosuppression arises from an imbalance 
between activating and inhibitory signals that regulate immune cell function, as well as 
overproduction of immunosuppressive cytokines such as TGFby the tumor mass68,69. 
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Transplantation of aLT into the renal subcapsular space 63,70 or close to the pathogenic 
site might help supplement anti-tumor immune responses. Another example where 
aLT might be beneficial to boost immune activity would be to counteract the atrophy of 
primary lymphoid organs and SLO which occurs during aging and which leads to 
immunosenescence71,72.  
So far, tissue engineering has been most widely studied in a rodent model using splenic 
tissue. Several reports have shown that not only embryonic and newborn splenic 
transplantation 23,73, but also tissue-engineered spleen (TES) generated from splenic 
multicellular components loaded on a biodegradable polymer scaffold74, induce partial 
or sufficient immune responses to infection. These studies provide valuable 
information concerning the generation of artificial lymphoid tissues. However, this 
approach lacks versatility in a clinical setting where the use of biological material might 
not be feasible if tissue supply is limited. Optimized combinations of stromal or 
hematopoietic cells and soluble factors such as chemokines or cytokines captured on 
scaffolds will be required to achieve solid results with general versatility. To date, few 
studies have managed to combine structural formation of aLT with immune 
responsiveness. However, we transplantated a collagen sponge that contained the 
thymus-derived cell line TEL-2 that overexpressed LT, stromal cells and bone 
marrow-derived DCs, into the mouse renal subcapsular space [Figure-2A]. In 2-3 weeks, 
it was observed that the graft behaved as an artificial lymph node (aLN), that 
possessed structures similar to secondary lymphoid tissues, such as T and B cell 
segregated clusters, FDC and FRC networks in B cell and T cell areas respectively, 
together with HEV-like structures. The aLNs induced a strong secondary immune 
response in vivo, and the high responsiveness was confirmed by the accumulation of 
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memory and effector T cells as well as memory B cells in the aLNs 70. When the aLNs 
were re-transplanted into SCID mice, and followed by immunization, a robust 
secondary immune response was induced 63,70. 
 
In terms of an in vitro trial to create the human LN environment, it was demonstrated 
that antigen-specific B cell clusters could be observed in a bioreactor – an ex vivo 
culture device – containing a porous matrix with antigen-primed DCs75. Recently, 
potentially useful cell lines of artificial antigen-presenting cells (aAPC) were established 
for humans 76. These cells possess the capacity to stimulate ex vivo or in vivo 
production of cytotoxic T cells from naïve T cells 76. aAPC have also been made by 
covalently coupling antigen peptide-MHC complex and the B7.1 co-stimulatory 
molecule to magnetic beads. In vivo treatment with the aAPC induced significant or 
complete reduction of tumors in mice 77. Based on this data, the aAPC might be an 
effective tool for tumor immunotherapy. The newly established aAPC might be also 
applicable for generating aLT.  To apply artificial lymphoid tissues to human diseases, 
an in vivo human model would first have to be established, using knowledge from 
previous mouse experiments. There has been a much progress in the establishment 
and analysis of humanized mice 78-80. NOD/SCID/IL-2 receptor  chainnull mice 
reconstituted with human CD34+ hematopoietic stem cells develop a functional human 
hematopoietic and immune system. As a result, humanized mice are utilized as a 
human disease model. They can be experimentally manipulated and can be used to 
directly study infectious diseases, immunological disorders, as well as cancer therapy in 





The idea of generating aLT, especially tissue that is functionally similar to SLO and TLO, 
is a novel strategy to trigger ectopic adaptive immune responses in vivo, as well as to 
study the functions of these tissues. Progress in this area might be applied to both 
locally and systemic treat severe infection, autoimmune diseases, tumors, for example. 
From this point of view, trials for construction of human aLT are at a preliminary stage, 
but could be imperative in the future.  
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Left: During embryogenesis, SLO formation is triggered by the interaction between 
LT12 on LTi cells and LTR on LTo cells. LTR ligation leads to the expression of the 
adhesion molecules such as VCAM-1, ICAM-1 and MadCAM-1, lymphoid chemokines 
such as CXCL13, CCL19 and CCL21, RANKL and IL-7. RANKL and IL-7 receptor signaling 
on the recruited LTi cells further induces LT12 to form a positive feedback loop for 
lymphoid tissue formation. Induction of VEGF-C production by LTo cell promotes 
lymphangiogenesis. Thus, LTR signaling in LTo cells attracts and retains hematopoietic 
cells, and leads to vascularization through HEV and lymphatic vessels. Right: TLO arise 
during inflammation, infection and in some autoimmune diseases. There have been 
reported circumstantial evidences indicated that antigen stimulation and/or LTR 
signaling play an important role in TLO formation 8,9,12. At ectopic sites such as the 
synovial membrane or pancreas, specific stromal cell types produce chemokines in 
response to antigen stimulation. These stromal cells resemble LTo cells at lymphoid 
tissue anlagen of SLO and induce TLO formation.  Both SLO and TLO have 
well-organized structures that include segregated T and B cell areas, DCs in T cell area, 
FDC networks in B cell follicles and vascular networks (lymphatic vessels and HEV). 
Migration and proper positioning of lymphoid tissue-associated cells is controlled by 
chemokines that essential for SLO and TLO development and function. CCL19 and 
CCL21 expressed by LTo and DCs attract and retain T cells within an appropriate area. 
On HEV, CCL21 facilitates migration of cells into lymphoid tissue. CXCL13 expressed by 
FDCs retains B cells in follicles. 
 




Transplant of a collagen sponge containing bone marrow-derived and antigen-pulsed 
DCs and VCAM-1+ LTR+ LTa overexpressing stromal cells into the renal subcapsular 
space produces the artificial lymphoid tissue (aLT) three weeks later. The tissue grafts 
resembles LN and contains T cell and B cell clusters, FDC and FRC networks in B cell 
follicles and T cell areas respectively and HEV-like vascular structures 63. The aLT 
contains memory B and T cells, follicular helper T cells (Tfh) and other helper T cell 
subsets. The presence of these cell types was confirmed by re-transplanting the aLT 
into SCID mice and followed by immunization, which gave a robust  secondary 
immune response [62, 69]. In these mice antigen-specific high-affinity IgG-producing B 
cells were present in the spleen, LN and BM. The antigen-specific IgG reached 3-7 
mg/ml in the SCID mouse serum. Thus the aLT might be a suitable tool for the analysis 
of memory B cells and their niche, for characterization of Tfh and as an application to 
generate hybridomas secreting monoclonal high-affinity IgG class antibody with a high 
efficiency. 
(B) aLT suppresses tumor growth in mice that have received tumor resection. When 
re-transplanted into SCID mice carrying the same tumors as in the original mice, aLT 
also suppress existing tumors. These data suggest that aLT may be applicable not only 
for enhancing antibody-mediated immune responses but also as a new strategy for 
cancer immunotherapy. In case of aLT use for immunotherapy, there might be a 
possibility that pathological lymphoid or myeloid cells co-opt the artificial lymphoid 
tissues and use the tissues to exacerbate the pathological response or induce 
unfavorable immune response(s) against the recipient. This point should be taken in 
consideration in a further trial for synthesis of artificial immune tissues/organs. 
(C) aLT synthesized in the bacterial or viral antigen-immunized mice may also exhibit an 
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